韩国2023年糖尿病病事实表 在韩国糖尿病病事实表
Nam Hoon Kim1, Mi-Hae Seo2, Jin Hyung Jung3
1Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Diabetes & metabolism journal
|March 18, 2024
概括
糖尿病病 (DKD) 影响超过四分之一的韩国成人患有糖尿病,增加心血管疾病和死亡的风险. 与糖尿病相关的末期病 (ESKD) 发病率正在上升,特别是在老年人群中.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 糖尿病病 (DKD) 和与糖尿病相关的末期病 (ESKD) 给健康带来了重大挑战.
- 了解他们在韩国的患病率,并发症和管理对于公共卫生倡议至关重要.
研究的目的:
- 调查韩国DKD和与糖尿病相关的ESKD的流行,发病率,并发症和治疗情况.
- 评估ESKD发病率的趋势和对DKD的关键药物 (RAS抑制剂,SGLT2抑制剂) 的使用.
- 评估DKD阶段与动脉样硬化心血管疾病 (ASCVD) 和死亡率风险之间的关联.
主要方法:
- 利用韩国国家健康和营养检查调查 (2019-2021) 调查DKD流行率和并发症控制率.
- 分析了韩国医疗保险服务数据库 (2008-2019) 的糖尿病相关的ESKD趋势和药物使用情况.
- 在糖尿病患者中,定义的DKD是白尿或估计的淋巴球过率 (eGFR) <60mL/min/1.73m2.
主要成果:
- 患有糖尿病的韩国成年人 (≥30岁) 的DKD患病率为25.4%;高血压,失脂症和肥胖是常见的并发症,对照率较低.
- 与糖尿病相关的ESKD的发生率和患病率一直在稳步增加,特别是在老年人中.
- 到2019年,减少eGFR的患者使用SGLT2抑制剂增加到5.94%,而大约70%的DKD患者使用RAS抑制剂.
- DKD阶段与ASCVD风险和死亡率的增加显著相关.
结论:
- 韩国糖尿病患者中DKD的流行率很高,是心血管疾病发病率和死亡率的独立风险因素.
- 对DKD患者来说,密集管理糖尿病和相关并发症是必不可少的.
- 与糖尿病相关的ESKD患病率不断上升,特别是在老年人中,需要紧急关注和干预策略.
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
533
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
533
Dialysis
309
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
309
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Internal Anatomy of the Kidney
1.6K
The kidneys are essential organs in the human body, performing a myriad of tasks that maintain homeostasis and overall health.
Anatomical Position and Dimensions
The kidneys are retroperitoneal organs positioned against the posterior abdominal wall on either side of the spine, roughly between the twelfth thoracic and third lumbar vertebrae. Each kidney is typically 10-12 cm long, 5-6 cm wide, and 3-4 cm thick, weighing about 150 grams.
Renal Cortex
The outermost region of the kidney is the...
Anatomical Position and Dimensions
The kidneys are retroperitoneal organs positioned against the posterior abdominal wall on either side of the spine, roughly between the twelfth thoracic and third lumbar vertebrae. Each kidney is typically 10-12 cm long, 5-6 cm wide, and 3-4 cm thick, weighing about 150 grams.
Renal Cortex
The outermost region of the kidney is the...
1.6K
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184


